Silibinin blocks the ability of TIME to support the growth of premalignant lesions via suppression of the NF-κB signaling pathway and pro-inflammatory cytokines, a mechanism highly relevant to estrogen receptor-negative cancers, where inflammatory pathways are often the ones resisting [57]. Here, NFKB1 is linked to cancer.